What benefits are associated with PT-141?

PT-141 is studied for: centrally mediated sexual arousal via MC3R and MC4R agonism, FDA-approved as Vyleesi (bremelanotide) for HSDD in premenopausal women, off-label use in men for erectile dysfunction and libido, nausea and flushing reported in ~40% of users — dose-timing management. This reflects the research literature catalogued on PeptideBase — educational only, not medical advice.

Educational use only — not medical advice

Research library

PT-141 benefits

From the PeptideBase research library. Educational only — not medical advice.

Studied effects

centrally mediated sexual arousal via MC3R and MC4R agonism
FDA-approved as Vyleesi (bremelanotide) for HSDD in premenopausal women
off-label use in men for erectile dysfunction and libido
nausea and flushing reported in ~40% of users — dose-timing management

Mechanism

PT-141 is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) that activates melanocortin receptors (MC3R and MC4R) in the central nervous system, particularly within the hypothalamus. Unlike peripherally acting agents, it modulates sexual arousal at the CNS level via dopaminergic pathways, independent of vascular mechanisms. Bremelanotide received FDA approval as Vyleesi for hypoactive sexual desire disorder in premenopausal women.